Circulating Tumor Cell (CTC) Market to Escalate to USD 28,300 Mn. by 2023

Pune, India, October, 2018 /press release/- Market Research Future Published a Half-Cooked Research Report on  Circulating Tumor Cell   Market Research Report.

Circulating tumor cell (CTC) is a rare cancer cell that is released into the bloodstream to gain the potential to provide vital information about a person’s specific cancer.   However, the clear correlation established between the number of these tumor cells and disease progression that could deliver a promise of clinical application of CTCs as a 'liquid biopsy' has not been so fruitful because of the rarity of these cells leading to posing challenges for detection and analysis using the current molecular biology techniques.

However, knowing the significance of CTC in cancer treatments, off late, many innovative researches have been conducted which also have delivered good outcomes, giving a fresh outlook to cancer and its treatments.  Some of these researches have presented the world with the merit techniques and measurement tools which would be helpful to potentially figure out which drugs would work best for each person before even starting treatment. Such tools can really help to customize treatments, using drugs that can target proteases on the patients who would actually benefit from it.

Thus the importance of circulating tumor cells proving to be vital in effective cancer treatment which is increasing CTCs market prominence and its market size. Resultantly, the CTC market is accruing vastly.  Undoubtedly, technological advancements in medical science & biotechnology escalated the CTC market on the global platform, bringing about betterments which could then improve the outlook for cancer treatments.

Acknowledging the traction, the market is garnering today; Market Research Future (MRFR) in its recently published study report asserts that the value of global circulating tumor cell market will be escalated to USD 28,300 Mn. by 2023 from USD 9,393.1 Mn. (in 2017). The CTC market will achieve this phenomenal growth registering an equally remarkable CAGR during the forecast period (2017 – 2023).

Additional factors substantiating the market growth include increasing per capita healthcare expenditures, increasing population, exposures to harmful radiation, and the heredity reasons and genetic mutations (abnormal changes) that could cause cancer. Well-spread awareness among the researchers about the vital role the CTC could play in delivering the effective cancer treatment.

Further substantial investments that are getting transpired in the R&D projects are in turn, paying off well bringing up the novelties and developments in the CTC mechanisms, which as a result are fostering the market growth. 

 Unavailability of comprehensive treatments especially in the developing regions presages the large scope for the market to evolve further, prompting significant investments for bringing betterments.

However, the rarity of circulating tumor cells is predominant factor hampering the market growth of CTC, limiting researches based on it.

Access Report @ https://www.marketresearchfuture.com/reports/circulating-tumor-cell-market-1362

Global Circulating Tumor Cell Market – Segments

MRFR has segmented its analysis into four Key dynamics for an easy grasp;

By Applications     : Clinical, Research, and Drug Development among others.

By Technologies    : CTC Enrichment, CTC Detection, and Combined Enrichment and Separation of CTC (CTC analysis) among others.

By End-Users          : Hospital & Clinics, Research & Academic Institutes, and Diagnostic Centers among others.

By Regions              :  APAC, North America, Europe, and the Rest-of-the-World.

Global Circulating Tumor Cell Market – Geographical Analysis

The North American region leads the circulating tumor cell market globally; the growth is largely supported by the U.S. with the increasing prevalence of types of cancer as consequences of the wrong lifestyle.  Besides, technological advancements getting transpired in the medical science and biotechnology alongside the substantial healthcare expenditure support the market growth.

The European region stands as another lucrative market for the circulating tumor cell. The market is growing owing to the increasing number of cancer patients in the region. Furthermore, the proliferation of advanced treatment facilities alongside the availability of skilled medical professionals, and the government support for research & development drives the market in the region. Moreover, factors such as technological advancement and well-spread awareness among people towards cancer and its consequences drive the growth of the regional market.

The CTC market in the Asia Pacific region is emerging as a promising market owing to the increasing number of cancer patients.  Factors substantiating market growth include the increasing prevalence of cancer, spreading awareness among people about cancer, and the availability of new treatment methods. Proliferating markets in China and India majorly contribute to the market growth in the region.

Global Circulating Tumor Cell Market – Competitive Landscape

The global CTC market appears intensely competitive with the several large and small players forming a competitive edge in the market incorporating strategic partnership, collaboration, acquisition, expansion, and technology launch.  Significant investments are transpired in the field to bring innovations to the therapy and clinical trials.

Key Players:

Some of the eminent leaders of the market include Greiner Bio-One International GmbH, Ikonisys Inc., Thermo Fisher Scientific, STEMCELL Technologies, SRI International, Miltenyi Biotec, QIAGEN Hannover (QIAGEN), Menarini Silicon Biosystems, F. Hoffmann-La Roche Ltd, Fluxion Biosciences, Inc., NanoString Technologies, Inc, GE Healthcare, Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation), ApoCell, Celltraffix Inc., and Epic Lifesciences.

Industry/ Innovation/Related News:

September 17, 2018 – Scientists at the University of California, Los Angeles (US) published in the Proceedings of the National Academy of Sciences the study of a mechanism for characterizing the function of rare tumor cells which they have developed. 

These researchers have created a quick and effective mechanism to measure how these cells perform functions that drive the disease, such as producing proteins that degrade tissue. Their findings could lead to more personalized treatments for people with cancer.

September 19, 2018 – ApoCell, Inc. (US), a leader global in specialty clinical Research Company involved in the capture and analysis of CTC, unveiled the biomarker results from the BEACON Phase 3 clinical trial utilizing Apocell's proprietary circulating tumor cell enrichment system, ApoStream®.  It is one of its own kind of publication that shows changes in a therapeutic target biomarker detected in CTCs that impacts overall survival in an important subset of metastatic breast cancer (MBC) patients.